IPAR

Publicly Available Assessment Report for a Veterinary Medicinal Product

CORTEXONAVET 2 mg/ml solution for injection for cattle, horses, pigs, dogs and cats

PRODUCT SUMMARY

EU Procedure number	IE/V/0351/001/DC
Name, strength and pharmaceutical form	CORTEXONAVET 2 mg/ml solution for injection for cattle, horses, pigs, dogs and cats
Active substance(s)	Dexamethasone (as dexamethasone sodium phosphate)
Applicant	Laboratorios Syva, S.A.U Avda Párraco Pablo Díez 49-57 (24010) León Spain
Legal basis of application	Generic application in accordance with Article 13(1) of Directive 2001/82/EC as amended.
Date of completion of procedure	18/11/2015
Target species	Cattle, horses, pigs, dogs and cats
Indication for use	<u>In horses, cattle, pigs, dogs and cats:</u> Treatment of inflammatory or allergic conditions. <u>In cattle:</u> Treatment of primary ketosis (acetonaemia). Induction of parturition <u>In horses:</u> Treatment of arthritis, bursitis or tenosynovitis.

ATCvet code	QH02AB02
Concerned Member States	AT, BE, BG, ES, HR, HU, IT, PL, PT, RO

PUBLIC ASSESSMENT REPORT

The public assessment report reflects the scientific conclusion reached by the HPRA at the end of the evaluation process and provides a summary of the grounds for approval of the marketing authorisation for the specific veterinary medicinal product. It is made available by the HPRA for information to the public, after the deletion of commercially confidential information. The legal basis for its creation and availability is contained in Article 25.4 of EC Directive 2001/82/EC as amended by Directive 2004/28/EC for veterinary medicinal products. It is a concise document which highlights the main parts of the documentation submitted by the applicant and the scientific evaluation carried out by the HPRA leading to the approval of the product for marketing in Ireland.

The Summary of Product Characteristics (SPC) for this product is available on the HPRA's website.

I. SCIENTIFIC OVERVIEW

The product is produced and controlled using validated methods and tests, which ensure the consistency of the product released on the market.
It has been shown that the product can be safely used in the target species.
The product is safe for the user, the consumer of foodstuffs from treated animals and for the environment, when used as recommended.Suitable warnings and precautions are indicated in the SPC.
The efficacy of the product was demonstrated according to the claims made in the SPC.
The overall benefit/risk analysis is in favour of granting a marketing authorisation.

II. QUALITY ASPECTS

A.Qualitative and Quantitative Particulars

The product contains 2 mg/ml dexamethasone as dexamethasone sodium phosphate and the excipients benzyl alcohol, sodium citrate, sodium chloride, sodium hydroxide, citric acid and water for injections.
The container/closure system is a colourless, Type I glass vial containing 50 ml or 100 ml, closed with a bromobutyl Type I rubber stopper and sealed with an aluminium cap.

The product is an established pharmaceutical form and its development is adequately described in accordance with the relevant European guidelines.

B.Method of Preparation of the Product

The product is manufactured fully in accordance with the principles of good manufacturing practice at a licensed manufacturing site.
Process validation data for the manufacturing process has been presented in accordance with the relevant European guidelines.

C.Control of Starting Materials

The active substance is dexamethasone as dexamethasone sodium phosphate, an active substance described in the European Pharmacopoeia. The active substance is manufactured in accordance with the principles of good manufacturing practice.
The active substance specification is considered adequate to control the quality of the material. Batch analytical data demonstrating compliance with this specification has been provided.
Specific Measures concerning the Prevention of the Transmission of Animal Spongiform Encephalopathies
There are no substances within the scope of the TSE Guideline present or used in the manufacture of this product.

D.Control on Intermediate Products

Not applicable.

E.Control Tests on the Finished Product

The finished product specification controls the relevant parameters for the pharmaceutical form. The tests in the specification, and their limits, have been justified and are considered appropriate to adequately control the quality of the product.
Satisfactory validation data for the analytical methods has been provided.
Batch analytical data from the proposed production site has been provided demonstrating compliance with the specification.

F.Stability

The active substance is fully tested to ensure compliance with its specification immediately prior to its use in manufacture of the product.
Stability data on the finished product has been provided in accordance with applicable European guidelines, demonstrating the stability of the product throughout its shelf life when stored under the approved conditions.

G.Other Information

Not applicable.

III SAFETY AND RESIDUES ASSESSMENT (PHARMACO-TOXICOLOGICAL)

This application was for CORTEXONAVET 2 mg/ml solution for injection for cattle, horses, pigs, dogs and cats. The product contains dexamethasone as active substance. The application was submitted using the decentralised application

procedure in the RMS and two CMSs. The application was for a generic product and was submitted in accordance with Article 13.1 of Directive 2001/82/EC, as amended.

The reference product cited by the applicant was Dexadreson 2 mg/ml Solution for Injection (VPA 10996/027/001 - Intervet Ireland Ltd.), first authorised in the RMS in October 1989.

The applicant satisfactorily demonstrated the essential similarity between the candidate formulation and the reference product by means of comparative analytical studies. It was accepted that the candidate formulation is essentially similar to the reference product in terms of the active substance and the excipients.

It was therefore accepted that the candidate product may be considered bioequivalent with the reference product.

Further, the candidate formulation will be administered to the same target species using the same posology and routes of administration already approved for the reference product.

Given the essential similarity with the reference product, an exemption from the requirement to demonstrate *in-vivo*bioequivalence was accepted.

III.ASafety Testing

Pharmacological Studies

As this was a generic application submitted in accordance with Article 13 of Directive 2001/82/EC, as amended and bioequivalence with the reference product was accepted, the applicant was not required to provide the results of pharmacological studies.

Toxicological Studies

As this was a generic application submitted in accordance with Article 13 of Directive 2001/82/EC, as amended and bioequivalence with the reference product was accepted, the applicant was not required to provide the results of toxicological studies.

User Safety

A user safety assessment was provided. Given that the candidate formulation was accepted as being essentially similar to the reference product and is to be indicated for use in the same target species using the same posology and routes of

administration, it was therefore accepted that the user of the product will not be exposed to a greater amount of the candidate formulation when compared to the reference product when handling, using, storing and disposing of the product.

The proposed user safety warnings are in line with those approved for the reference product and other similar products recently authorised via European procedures. Warnings and precautions as listed on the product literature are adequate to ensure safety to users of the product.

Environmental Risk Assessment

Phase I
The applicant provided a Phase I environmental risk assessment. Based on the results of the Phase I assessment, it was concluded that a Phase II assessment was not required.

Conclusion
The product is not expected to pose an unacceptable risk for the environment when stored, handled, administered and disposed of in accordance with the recommendations included in the SPC.

III.BResidues Documentation

Residue Studies

No residue study data was provided. Given that bioequivalence between candidate and reference product formulations was satisfactorily demonstrated, the absence of injection site residue depletion studies conducted with the candidate formulation could be accepted, as the depletion of residues from the intramuscular injection site is not expected to differ between candidate and reference formulations.

It was concluded that the candidate formulation will not present an unacceptable risk for the consumer of products derived from animals administered the product.

MRLs

Dexamethasone is listed in Table I of the Annex to Commission Regulation (EU) No 37/2010 as follows:

Pharmacologically active substance	Marker residue	Animal species	MRL	Target tissue

Dexamethasone	Dexamethasone	Bovine, caprine, porcine, Equidae	0.75 µg/kg 2 µg/kg 0.75µg/kg	Muscle Liver Kidney
		Bovine, caprine,	0.3 µg/kg	Milk

Withdrawal Periods

The candidate formulation was accepted as being bioequivalent to that of the reference product. Both products are to be administered using the same posology and route of administration in the same target species. It was therefore concluded that no difference in depletion of residues in the target animal is to be expected.

Consequently, it was accepted that the withdrawal periods for meat and offal and milk approved for the reference product, are also applicable to this generic product and are considered adequate to ensure consumer safety.

IV. CLINICAL ASSESSMENT

As this was a generic application according to Article 13, and bioequivalence with a reference product has been demonstrated, efficacy studies were not required. The efficacy claims for this product are equivalent to those of the reference product.

IV.APre-Clinical Studies(pharmaceuticals only)
Tolerance in the Target Species of Animals
No target animal tolerance studies were conducted. Given that this was a generic application and the candidate formulation will be administered to the same target species using the same posology and routes of administration already approved for the reference product, it was concluded that no difference in tolerance in the target species is to be expected between candidate and reference product formulations. The omission of target animal tolerance data was therefore accepted.

IV.B Clinical Studies As this is a generic application according to Article 13, and bioequivalence with a reference product has been demonstrated, clinical studies and field trials were not required. The efficacy claims for this product are equivalent to those of the reference product.

V. OVERALL CONCLUSION AND BENEFIT/RISK ASSESSMENT

The data submitted in the dossier demonstrate that when the product is used in accordance with the Summary of Product Characteristics, the benefit/risk profile for the target species is favourable and the quality, safety and efficacy of the product are acceptable.

VI. POST-AUTHORISATION ASSESSMENTS

None.